Dutch national guidelines for locally recurrent rectal cancer

IF 9.6 1区 医学 Q1 ONCOLOGY Cancer treatment reviews Pub Date : 2024-04-19 DOI:10.1016/j.ctrv.2024.102736
Floor Piqeur , Davy M.J. Creemers , Evi Banken , Liën Coolen , Pieter J. Tanis , Monique Maas , Mark Roef , Corrie A.M. Marijnen , Irene E.G. van Hellemond , Joost Nederend , Harm J.T. Rutten , Heike M.U. Peulen , Jacobus W.A. Burger
{"title":"Dutch national guidelines for locally recurrent rectal cancer","authors":"Floor Piqeur ,&nbsp;Davy M.J. Creemers ,&nbsp;Evi Banken ,&nbsp;Liën Coolen ,&nbsp;Pieter J. Tanis ,&nbsp;Monique Maas ,&nbsp;Mark Roef ,&nbsp;Corrie A.M. Marijnen ,&nbsp;Irene E.G. van Hellemond ,&nbsp;Joost Nederend ,&nbsp;Harm J.T. Rutten ,&nbsp;Heike M.U. Peulen ,&nbsp;Jacobus W.A. Burger","doi":"10.1016/j.ctrv.2024.102736","DOIUrl":null,"url":null,"abstract":"<div><p>Due to improvements in treatment for primary rectal cancer, the incidence of LRRC has decreased. However, 6–12% of patients will still develop a local recurrence. Treatment of patients with LRRC can be challenging, because of complex and heterogeneous disease presentation and scarce − often low-grade − data steering clinical decisions. Previous consensus guidelines have provided some direction regarding diagnosis and treatment, but no comprehensive guidelines encompassing all aspects of the clinical management of patients with LRRC are available to date. The treatment of LRRC requires a multidisciplinary approach and overarching expertise in all domains. This broad expertise is often limited to specific expert centres, with dedicated multidisciplinary teams treating LRRC. A comprehensive, narrative literature review was performed and used to develop the Dutch National Guideline for management of LRRC, in an attempt to guide decision making for clinicians, regarding the complete clinical pathway from diagnosis to surgery.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"127 ","pages":"Article 102736"},"PeriodicalIF":9.6000,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S030573722400063X","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Due to improvements in treatment for primary rectal cancer, the incidence of LRRC has decreased. However, 6–12% of patients will still develop a local recurrence. Treatment of patients with LRRC can be challenging, because of complex and heterogeneous disease presentation and scarce − often low-grade − data steering clinical decisions. Previous consensus guidelines have provided some direction regarding diagnosis and treatment, but no comprehensive guidelines encompassing all aspects of the clinical management of patients with LRRC are available to date. The treatment of LRRC requires a multidisciplinary approach and overarching expertise in all domains. This broad expertise is often limited to specific expert centres, with dedicated multidisciplinary teams treating LRRC. A comprehensive, narrative literature review was performed and used to develop the Dutch National Guideline for management of LRRC, in an attempt to guide decision making for clinicians, regarding the complete clinical pathway from diagnosis to surgery.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
荷兰局部复发直肠癌国家指南
由于原发性直肠癌治疗方法的改进,LRRC 的发病率有所下降。然而,仍有 6-12% 的患者会出现局部复发。LRRC 患者的治疗具有挑战性,因为疾病表现复杂多样,而且指导临床决策的数据稀缺,通常是低级别数据。以前的共识指南为诊断和治疗提供了一些方向,但迄今为止还没有涵盖 LRRC 患者临床治疗各个方面的全面指南。LRRC 的治疗需要多学科方法和所有领域的总体专业知识。这种广泛的专业知识往往局限于特定的专家中心,由专门的多学科团队来治疗 LRRC。我们进行了全面的叙述性文献综述,并以此为基础制定了荷兰国家 LRRC 管理指南,试图指导临床医生就从诊断到手术的完整临床路径做出决策。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cancer treatment reviews
Cancer treatment reviews 医学-肿瘤学
CiteScore
21.40
自引率
0.80%
发文量
109
审稿时长
13 days
期刊介绍: Cancer Treatment Reviews Journal Overview: International journal focused on developments in cancer treatment research Publishes state-of-the-art, authoritative reviews to keep clinicians and researchers informed Regular Sections in Each Issue: Comments on Controversy Tumor Reviews Anti-tumor Treatments New Drugs Complications of Treatment General and Supportive Care Laboratory/Clinic Interface Submission and Editorial System: Online submission and editorial system for Cancer Treatment Reviews
期刊最新文献
Editorial Board Optimizing outcomes and personalizing care with targeted agents in advanced cholangiocarcinoma PARP inhibitors in gliomas: Mechanisms of action, current trends and future perspectives Local administration of immunotherapy for patients with skin cancer: A systematic review False Positive Rate from Prospective Studies of PET-CT in Cutaneous Malignant Melanoma: A Systematic Review and Meta-Analysis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1